SHANGHAI – Alphamab Oncology Co. Ltd., of Suzhou, China, has kicked off a phase I study in Australia for KN-046, a PD-L1/CTLA-4, a potentially first-in-class bispecific that combines two domain antibodies fused with IgG Fc.